Перегляд вихідного коду сторінки Key Arguments Why IPI-145 Are Improved Than Its Opponents

588). They had 15 multiple births (all twins) in GnRH agonist group as compared with only two multiple births (all twins) in placebo group but there were no multiple pregnancies in our study. This may be due to fewer samples in our study. On the other hand, our population were women with 2 or more IVF/ICSIET failures with good quality embryos and there were lower pregnancy rates among these women (20). Tesarik et al. (2006) reported significant increase in clinical implantation rates (29.8% vs. 18.2%, p [https://en.wikipedia.org/wiki/Oxacillin Oxacillin] group in GnRH agonist ovarian stimulation cycle. They also reported significant improvement in clinical implantation (27.1% vs. 17.4%, p [http://www.selleckchem.com/products/BKM-120.html mTOR inhibitor] in GnRH antagonist ovarian stimulation cycles and also a trend toward a higher clinical pregnancy rate (p = 0.083) in GnRh agonist group. Razieh et al. (2009) observed that administration of 0.1 mg of GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo (13). In a study by Isik et al. (2009), the same results were demonstrated. All cases in that study received intravaginal micronized progesterone [http://www.selleckchem.com/products/ipi-145-ink1197.html IPI-145] (600 mg daily) for luteal phase support in GnRH antagonist during ovarian stimulation cycles. Although the number and the quality of embryos transferred were similar in the two groups, the women in the luteal phase agonist group (0.5 mg leuprolide acetate, subcutaneously on day 6 after ICSI) had significantly higher rates of implantation and clinical pregnancy rates (p